AVROBIO, Inc. (AVRO) News

AVROBIO, Inc. (AVRO): $0.87

0.00 (-0.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AVRO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 382

in industry

Filter AVRO News Items

AVRO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AVRO News Highlights

  • For AVRO, its 30 day story count is now at 6.
  • Over the past 14 days, the trend for AVRO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about AVRO are GENE, NOV and PATH.

Latest AVRO News From Around the Web

Below are the latest news stories about AVROBIO INC that investors may wish to consider to help them evaluate AVRO as an investment opportunity.

AVROBIO to Share Comprehensive Gaucher Disease Program Update

CAMBRIDGE, Mass., November 17, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will host a virtual Gaucher Disease Program Update for analysts and investors on Wednesday, Dec. 7, 2022, starting at 8 am ET.

Yahoo | November 17, 2022

AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the third quarter ended Sept. 30, 2022 and provided a business update. “We had a steady cadence of news this quarter highlighting our steadfast efforts to bring our gene therapies to patients,” said Geoff MacKay, president and CEO of AVROBIO. “We look forward to providing a comprehensive upd

Business Wire | November 8, 2022

AVROBIO GAAP EPS of -$0.52 beats by $0.01

AVROBIO press release (AVRO): Q3 GAAP EPS of -$0.52 beats by $0.01.As of September 30, 2022, AVROBIO had $116.0 million in cash and cash equivalents, as compared to $189.6 million…

Seeking Alpha | November 8, 2022

AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit

CAMBRIDGE, Mass., November 07, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced senior management will be participating in a virtual panel titled "Genomic Medicines – Evolving Regulatory Environment and Path to Approval" at the Sixth Annual Barclays Gene Editing/Therapy Summit on Monday, Nov. 14, 2022 at 12:30 PM ET.

Yahoo | November 7, 2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., November 03, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 13,000 restricted stock units (RSUs) to two new employees as inducement awards under the company’s 2019 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Yahoo | November 3, 2022

Avrobio stock rises on FDA rare pediatric disease tag for Gaucher disease gene therapy

The U.S. Food and Drug Administration ((FDA)) granted rare pediatric disease designation to Avrobio''s (AVRO) gene therapy AVR-RD-02 to treat Gaucher disease ((GD)).Gaucher disease is…

Seeking Alpha | October 27, 2022

AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease

CAMBRIDGE, Mass., October 27, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-02, a first-in-class investigational gene therapy that genetically modifies patients’ own hematopoietic stem cells (HSCs) to treat Gaucher disease, a rare lysosomal disorder that can lead to multiorgan patho

Yahoo | October 27, 2022

Needham Sticks to Its Buy Rating for Avrobio (AVRO)

Needham analyst Gil Blum maintained a Buy rating on Avrobio (AVRO - Research Report) on October 20 and set a price target of $6.00. The company's shares opened today at $0.67.Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Rocket Pharmaceuticals, and Aeglea Biotherapeutics. According to TipRanks, Blum has an average return of -24.7% and a 27.84% success rate on recommended stocks. Currently, the analyst consensus on Avrobio is a Moderate Buy with an average price target of $6.00.See the top stocks recommended by analysts >>Based on Avrobio's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $28.

Austin Angelo on TipRanks | October 25, 2022

AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

CAMBRIDGE, Mass., October 25, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the sixth and final patient has been dosed in the collaborator-sponsored, Phase 1/2 clinical trial of an investigational gene therapy for the treatment of cystinosis. Cystinosis is a life-threatening disease that causes progressive multi-organ damage, including early, acute kidney disease progressing to end

Yahoo | October 25, 2022

After Sinking 11.13% During Past Week, Is AVROBIO Inc. (NASDAQ: AVRO) Still A Buy?

AVROBIO Inc. (NASDAQ:AVRO)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 1.57. At the close of trading, the stock’s price was $0.65, to imply a decrease of -1.01% or -$0.01 in intraday trading. The AVRO share’s 52-week high remains $6.62, putting it -918.46% down since that peak … After Sinking 11.13% During Past Week, Is AVROBIO Inc. (NASDAQ: AVRO) Still A Buy? Read More »

Marketing Sentinel | October 22, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6357 seconds.